77 results
8-K/A
EX-10.2
CHRS
Coherus Biosciences Inc
21 May 24
Financial Statements and Exhibits
5:14pm
-Marketing Approval studies, post-launch marketing, promoting, detailing, marketing research, distributing, customer service, or transporting such Product … with customer prepayments and deposits, and (iv) prepaid or deferred revenue arising in the ordinary course of business), including (A) any obligation
8-K/A
EX-10.1
CHRS
Coherus Biosciences Inc
21 May 24
Financial Statements and Exhibits
5:14pm
-your-customer” and anti-money laundering rules and regulations, including the U.S.A. Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26 … are not more than one hundred and twenty (120) days past due or subject to a bona fide dispute, (iii) liabilities associated with customer prepayments
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
9 May 24
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
4:17pm
, a novel and proprietary state-of-the-art delivery system for pegfilgrastim-cbqv, was launched in February 2024. High customer demand and confirmed
8-K
EX-99.1
3qmy jutov
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
8-K
EX-2.1
5du5xfgvrpt056
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
8-K/A
EX-99.1
dv8b1jf6ak 9k0p264x
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
425
6h4le
16 Jun 23
Business combination disclosure
8:08am
425
99mhd1
16 Jun 23
Business combination disclosure
7:09am
8-K
EX-2.1
z1task
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am